Lansing, Michigan – For people who spent years paying for certain generic prescriptions, an old pharmacy bill could now be worth another look. Michigan Attorney General Dana Nessel is urging consumers to check whether purchases made as far back as 2009 qualify them for money from a multistate settlement.
About $96.5 million in settlements involving several generic drug manufacturers is at the center of the compensation effort. The money comes from agreements resolving claims that companies conspired to inflate generic drug prices, potentially leaving consumers paying more than they otherwise would have.
The U.S. District Court for the District of Connecticut recently granted preliminary approval to a distribution plan submitted by Michigan and a coalition of 47 other states and territories. The plan is intended to return millions of dollars to people potentially affected by elevated prices for drugs covered by the settlements. Consumers can submit a claim online.
Settlements previously announced with Glenmark, Lannett, Bausch, Apotex, Heritage and Heritage’s parent company, Emcure, total approximately $96.5 million. The broader litigation continues against other drug manufacturers.
“Consumers who paid the high price of generic drugs because companies placed profits over fairness are now entitled to compensation,” Nessel said.
“This settlement holds companies accountable for conspiring to inflate drug prices. If you purchased certain generic medications during the covered period, I encourage you to check your eligibility and file a claim. My office is committed to putting money back into the hands of those it belongs to: the consumers.”
People who purchased one of the generic medications on the settlement drug list between May 2009 and December 2019 may qualify. Consumers can also visit the AG Generic Drugs website, email [email protected] or call 1-866-290-0182 for information about eligibility.
Michigan’s involvement goes back a decade. The state joined a series of antitrust cases beginning in 2016, followed by additional complaints involving major generic drug manufacturers and dozens of medications. A fourth complaint was filed in 2026 against Novartis AG, Sandoz Group AG and Sandoz AG.
According to the states, their investigations drew on millions of documents, extensive phone records and cooperating witnesses. The complaints allege that competing executives regularly communicated and used phrases such as “fair share” and “playing nice in the sandbox” while coordinating conduct that reduced competition and increased prices.
For consumers, however, the immediate issue is simpler: checking an old prescription history could determine whether some of that settlement money is coming back to them.